2025-03-19 Investor Supplementary Materials of Consolidated Financial Results for the Six Months Ended January 3 2025-03-13 Investor (Delayed)Summary of Consolidated Financial Results for the Six Months Ended January 31, 2025 (Based on Japanese GAAP) 2025-02-12 Research and Development The establishment of World's first "CADASIL Drug Discovery Research Department" in collaboration with National Cerebral and Cardiovascular Center 2024-12-13 Investor (Delayed)Summary of Consolidated Financial Results for the Three Months Ended October 31, 2024 (Based on Japanese GAAP) 2024-09-30 Investor Notice of the 27th Annual General Meeting of Shareholders 2024-09-27 Investor (Delayed) Summary of Consolidated Financial Results for the Year Ended July 31, 2024 (Based on Japanese GAAP) 2024-06-28 Investor A milestone has been achieved as set forth in an Exclusive Licensing Agreement between PFI and Mitsubishi Tanabe Pharma Corporation for a New Investigational Therapeutic Antibody for autoimmune diseases 2024-06-11 Investor (Delayed)Summary of Consolidated Financial Results for the Nine Months Ended April 30, 2024 (Based on Japanese GAAP) 2024-05-28 Investor Company Research And Analysis Report（FISCO） 2024-03-15 Investor (Delayed)Summary of Consolidated Financial Results for the Six Months Ended January 31, 2024 (Based on Japanese GAAP) More